Hepatocellular Carcinoma and Statins

Area of Science:

• Pharmacology
• Oncology
• Hepatology

Background:

• HMG-CoA reductase inhibitors (statins) are primary treatments for dyslipidemia and coronary heart disease.
• Statins significantly reduce cardiovascular morbidity and mortality.
• Emerging evidence suggests statins offer benefits beyond cardiovascular health, including in non-alcoholic steatohepatitis and cancer.

Purpose of the Study:

• To review studies on statin use and cancer-associated mortality.
• To specifically examine the association between statins and liver cancer.
• To review proposed mechanisms for statins' chemo-preventive and antitumor effects.

Main Methods:

• Literature review of studies investigating statins and cancer.
• Focus on studies examining liver cancer outcomes.
• Analysis of proposed molecular mechanisms of statin action.

Main Results:

• Multiple studies indicate statin use is linked to reduced cancer-associated mortality across various cancer types.
• Evidence suggests potential benefits of statins in non-alcoholic steatohepatitis.
• Proposed mechanisms involve chemo-preventive and antitumor activities.

Conclusions:

• Statins demonstrate potential in reducing cancer mortality, including liver cancer.
• Understanding the mechanisms of statins' antitumor effects is crucial for therapeutic development.
• Statins may represent a novel therapeutic strategy for cancer prevention and treatment.